Although polices have been introduced to increase the use of generics and biosimilars, large differences remain in the price and uptake of these medicines between countries.
Vilazodone hydrochloride tablets and empagliflozin tablets had a market value of $469 million and roughly $3.4 billion respectively, for the 12 months ended September 2019.
Twenty-nine of the 48 novel drug approvals of 2019, or 60%, were designated in one or more expedited categories of Fast Track, Breakthrough, Priority Review, and/or Accelerated Approval.
